AF
CPRX

Allworth Financial’s Catalyst Pharmaceutical CPRX Stock Holding History

Allworth Financial’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56K Sell
1,781
-24,681
-93% -$728K ﹤0.01% 2383
2026
Q1 		$655K Sell
26,462
-2,127
-7% -$50.7K ﹤0.01% 849
2025
Q4 		$667K Sell
28,589
-706
-2% -$15.7K ﹤0.01% 819
2025
Q3 		$577K Buy
29,295
+8,323
+40% +$171K ﹤0.01% 839
2025
Q2 		$455K Buy
20,972
+20,705
+7,755% +$489K ﹤0.01% 865
2025
Q1 		$6.19K Hold
267
– – ﹤0.01% 2650
2024
Q4 		$6.11K Sell
267
-94
-26% -$2.02K ﹤0.01% 2665
2024
Q3 		$7.18K Hold
361
– – ﹤0.01% 2410
2024
Q2 		$6.12K Buy
361
+109
+43% +$1.7K ﹤0.01% 2425
2024
Q1 		$4.02K Sell
252
-19
-7% -$286 ﹤0.01% 2498
2023
Q4 		$4.56K Buy
271
+246
+984% +$3.36K ﹤0.01% 2308
2023
Q3 		$293 Buy
+25
New +$334 ﹤0.01% 3175
2023
Q1 		– Sell
-68
Closed -$1.26K – 3210
2022
Q4 		$1.26K Buy
68
+4
+6% +$62 ﹤0.01% 2397
2022
Q3 		$1K Buy
+64
New +$758 ﹤0.01% 2345

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Allworth Financial's CPRX Position: Q2 2026 in Review

Allworth Financial reduced its Catalyst Pharmaceutical (CPRX) stake by 93% in Q2 2026, selling an estimated $728K and leaving 1,781 shares worth $56K. The position accounts for ﹤0.01% of the portfolio, ranked #2383.

Allworth Financial first reported a position in CPRX in Q3 2022 and has held it in 14 quarters since. The position peaked at $667K in Q4 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Allworth Financial held 1,781 shares of Catalyst Pharmaceutical worth $56K as of Q2 2026.
  • Allworth Financial sold 24,681 Catalyst Pharmaceutical shares in Q2 2026, an estimated $728K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2383 holding.
  • Allworth Financial first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 14 quarters since.
  • Allworth Financial's Catalyst Pharmaceutical position peaked at $667K in Q4 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.